drugset / Trial / NCT00660218
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
Phase 1/2
Completed
53 enrolled
State University of New York - Upstate Medical University
CTI BioPharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This study involves two phases. Phase I of this study is designed to find out the maximum dose of paclitaxel poliglumex which can be safely given to subjects when combined with cetuximab and radiotherapy in head and neck cancer. Once the maximum safe dose of paclitaxel poliglumex is found, Phase II of the study will continue to find out whether the addition of paclitaxel poliglumex increases tumor response and survival compared to treatment with cetuximab and radiotherapy alone. An additional 20 patients have been added, to balance data. These patients must be HPV negative.
Timeline
- Start
- 2008-03
- Primary completion
- 2016-12
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 70 mg/m2 | Intravenous |
| Subject | paclitaxel poliglumex | Other / unclassified | 80 mg/m2 | Intravenous |